Rev-derived peptides inhibit HIV-1 replication by antagonism of Rev and a co-receptor, CXCR4

International Journal of Biochemistry and Cell Biology

Volumn 42, Issue 9, 2010, Pages 1482-1488

  Shimane, Kazuki ^a,b   Kodama, Eiichi N ^a,c   Nakase, Ikuhiko ^d   Futaki, Shiroh ^d   Sakurai, Yasuteru ^a,b   Sakagami, Yasuko ^a   Li, Xiaoguang ^c   Hattori, Toshio ^c   Sarafianos, Stefan G ^e   Matsuoka, Masao ^a  

^a KYOTO UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d KYOTO UNIVERSITY   (Japan)

^e University of Missouri   (United States)

Author keywords

Alpha helix; CXCR4; HIV 1; Inhibitor; Rev

Indexed keywords

ARGININE; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; PLERIXAFOR; REV PROTEIN; REV PROTEIN 1-21; REV PROTEIN 34-50; RNA BINDING PROTEIN; UNCLASSIFIED DRUG; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; PEPTIDE;

AMINO ACID SEQUENCE; ANTIVIRAL ACTIVITY; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN T CELL LEUKEMIA VIRUS 1; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; VIRUS ENTRY; VIRUS REPLICATION; ANTAGONISTS AND INHIBITORS; CELL LINE; CHEMISTRY; DRUG EFFECTS; FLOW CYTOMETRY; HIV INFECTIONS; PATHOGENICITY;

HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN T-LYMPHOTROPIC VIRUS 1;

ANTI-HIV AGENTS; CELL LINE; FLOW CYTOMETRY; HIV INFECTIONS; HIV-1; HUMANS; PEPTIDES; RECEPTORS, CXCR4; REV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; VIRUS REPLICATION;

EID: 77955096962     PISSN: 13572725     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biocel.2010.05.005     Document Type: Article

References (48)

1. Ahmed Y.F., Hanly S.M., Malim M.H., Cullen B.R., Greene W.C. Structure-function analyses of the HTLV-I Rex and HIV-1 Rev RNA response elements: insights into the mechanism of Rex and Rev action. Genes Dev 1990, 4:1014-1022.
2. Arakaki R., Tamamura H., Premanathan M., Kanbara K., Ramanan S., Katsura Mochizuki K., et al. T134, a small-molecule CXCR4 inhibitor, has no cross-drug resistance with AMD3100, a CXCR4 antagonist with a different structure. J Virol 1999, 73:1719-1723.
3. Baba M., Nishimura O., Kanzaki N., Okamoto M., Sawada H., Iizawa Y., et al. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc Natl Acad Sci U S A 1999, 96:5698-5703.
4. Battiste J.L., Mao H., Rao N.S., Tan R., Muhandiram D.R., Kay L.E., et al. Alpha helix-RNA major groove recognition in an HIV-1 rev peptide-RRE RNA complex. Science 1996, 273:1547-1551.
5. Bogerd H.P., Huckaby G.L., Ahmed Y.F., Hanly S.M., Greene W.C. The type I human T-cell leukemia virus (HTLV-I) Rex trans-activator binds directly to the HTLV-I Rex and the type 1 human immunodeficiency virus Rev RNA response elements. Proc Natl Acad Sci U S A 1991, 88:5704-5708.
6. Charpentier B., Stutz F., Rosbash M. A dynamic in vivo view of the HIV-I Rev-RRE interaction. J Mol Biol 1997, 266:950-962.
7. Daugherty M.D., D'Orso I., Frankel A.D. A solution to limited genomic capacity: using adaptable binding surfaces to assemble the functional HIV Rev oligomer on RNA. Mol Cell 2008, 31:824-834.
8. Dayton E.T., Powell D.M., Dayton A.I. Functional analysis of CAR, the target sequence for the Rev protein of HIV-1. Science 1989, 246:1625-1629.
9. Donzella G.A., Schols D., Lin S.W., Este J.A., Nagashima K.A., Maddon P.J., et al. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat Med 1998, 4:72-77.
10. Doranz B.J., Grovit-Ferbas K., Sharron M.P., Mao S.H., Goetz M.B., Daar E.S., et al. A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor. J Exp Med 1997, 186:1395-1400.
11. Dundr M., Leno G.H., Hammarskjold M.L., Rekosh D., Helga-Maria C., Olson M.O. The roles of nucleolar structure and function in the subcellular location of the HIV-1 Rev protein. J Cell Sci 1995, 108(Pt 8):2811-2823.
12. Este J.A., Telenti A. HIV entry inhibitors. Lancet 2007, 370:81-88.
13. Felber B.K., Drysdale C.M., Pavlakis G.N. Feedback regulation of human immunodeficiency virus type 1 expression by the Rev protein. J Virol 1990, 64:3734-3741.
14. Felber B.K., Hadzopoulou-Cladaras M., Cladaras C., Copeland T., Pavlakis G.N. rev protein of human immunodeficiency virus type 1 affects the stability and transport of the viral mRNA. Proc Natl Acad Sci U S A 1989, 86:1495-1499.
15. Fischer U., Huber J., Boelens W.C., Mattaj I.W., Luhrmann R. The HIV-1 Rev activation domain is a nuclear export signal that accesses an export pathway used by specific cellular RNAs. Cell 1995, 82:475-483.
16. Futaki S., Ishikawa T., Niwa M., Kitagawa K., Yagami T. Embodying a stable alpha-helical protein structure through efficient chemical ligation via thioether formation. Bioorg Med Chem 1997, 5:1883-1891.
17. Futaki S., Suzuki T., Ohashi W., Yagami T., Tanaka S., Ueda K., et al. Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. J Biol Chem 2001, 276:5836-5840.
18. Hammes S.R., Greene W.C. Multiple arginine residues within the basic domain of HTLV-I Rex are required for specific RNA binding and function. Virology 1993, 193:41-49.
19. Harada K., Martin S.S., Frankel A.D. Selection of RNA-binding peptides in vivo. Nature 1996, 380:175-179.
20. Harada K., Martin S.S., Tan R., Frankel A.D. Molding a peptide into an RNA site by in vivo peptide evolution. Proc Natl Acad Sci U S A 1997, 94:11887-11892.
21. Jain C., Belasco J.G. Structural model for the cooperative assembly of HIV-1 Rev multimers on the RRE as deduced from analysis of assembly-defective mutants. Mol Cell 2001, 7:603-614.
22. Jiang F., Gorin A., Hu W., Majumdar A., Baskerville S., Xu W., et al. Anchoring an extended HTLV-1 Rex peptide within an RNA major groove containing junctional base triples. Structure 1999, 7:1461-1472.
23. Kalland K.H., Szilvay A.M., Langhoff E., Haukenes G. Subcellular distribution of human immunodeficiency virus type 1 Rev and colocalization of Rev with RNA splicing factors in a speckled pattern in the nucleoplasm. J Virol 1994, 68:1475-1485.
24. Kjems J., Calnan B.J., Frankel A.D., Sharp P.A. Specific binding of a basic peptide from HIV-1 Rev. EMBO J 1992, 11:1119-1129.
25. Kodama E.I., Kohgo S., Kitano K., Machida H., Gatanaga H., Shigeta S., et al. 4'-Ethynyl nucleoside analogs: potent inhibitors of multidrug-resistant human immunodeficiency virus variants in vitro. Antimicrob Agents Chemother 2001, 45:1539-1546.
26. Lalezari J.P., Henry K., O'Hearn M., Montaner J.S., Piliero P.J., Trottier B., et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003, 348:2175-2185.
27. Lazzarin A., Clotet B., Cooper D., Reynes J., Arasteh K., Nelson M., et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 2003, 348:2186-2195.
28. Lin J.C., Barua B., Andersen N.H. The helical alanine controversy: an (Ala)6 insertion dramatically increases helicity. J Am Chem Soc 2004, 126:13679-13684.
29. Maeda K., Nakata H., Koh Y., Miyakawa T., Ogata H., Takaoka Y., et al. Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro. J Virol 2004, 78:8654-8662.
30. Malim M.H., Bohnlein S., Hauber J., Cullen B.R. Functional dissection of the HIV-1 Rev trans-activator-derivation of a trans-dominant repressor of Rev function. Cell 1989, 58:205-214.
31. Malim M.H., Cullen B.R. HIV-1 structural gene expression requires the binding of multiple Rev monomers to the viral RRE: implications for HIV-1 latency. Cell 1991, 65:241-248.
32. Malim M.H., Hauber J., Le S.Y., Maizel J.V., Cullen B.R. The HIV-1 rev trans-activator acts through a structured target sequence to activate nuclear export of unspliced viral mRNA. Nature 1989, 338:254-257.
33. Mann D.A., Mikaelian I., Zemmel R.W., Green S.M., Lowe A.D., Kimura T., et al. A molecular rheostat. Co-operative rev binding to stem I of the rev-response element modulates human immunodeficiency virus type-1 late gene expression. J Mol Biol 1994, 241:193-207.
34. Marqusee S., Robbins V.H., Baldwin R.L. Unusually stable helix formation in short alanine-based peptides. Proc Natl Acad Sci U S A 1989, 86:5286-5290.
35. Murakami T., Zhang T.Y., Koyanagi Y., Tanaka Y., Kim J., Suzuki Y., et al. Inhibitory mechanism of the CXCR4 antagonist T22 against human immunodeficiency virus type 1 infection. J Virol 1999, 73:7489-7496.
36. Nagahara H., Vocero-Akbani A.M., Snyder E.L., Ho A., Latham D.G., Lissy N.A., et al. Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migration. Nat Med 1998, 4:1449-1452.
37. Nameki D., Kodama E., Ikeuchi M., Mabuchi N., Otaka A., Tamamura H., et al. Mutations conferring resistance to human immunodeficiency virus type 1 fusion inhibitors are restricted by gp41 and Rev-responsive element functions. J Virol 2005, 79:764-770.
38. Olsen H.S., Cochrane A.W., Dillon P.J., Nalin C.M., Rosen C.A. Interaction of the human immunodeficiency virus type 1 Rev protein with a structured region in env mRNA is dependent on multimer formation mediated through a basic stretch of amino acids. Genes Dev 1990, 4:1357-1364.
39. Rimsky L., Hauber J., Dukovich M., Malim M.H., Langlois A., Cullen B.R., et al. Functional replacement of the HIV-1 rev protein by the HTLV-1 rex protein. Nature 1988, 335:738-740.
40. Seelamgari A., Maddukuri A., Berro R., de la Fuente C., Kehn K., Deng L., et al. Role of viral regulatory and accessory proteins in HIV-1 replication. Front Biosci 2004, 9:2388-2413.
41. Siomi H., Shida H., Nam S.H., Nosaka T., Maki M., Hatanaka M. Sequence requirements for nucleolar localization of human T cell leukemia virus type I pX protein, which regulates viral RNA processing. Cell 1988, 55:197-209.
42. Stauber R., Gaitanaris G.A., Pavlakis G.N. Analysis of trafficking of Rev and transdominant Rev proteins in living cells using green fluorescent protein fusions: transdominant Rev blocks the export of Rev from the nucleus to the cytoplasm. Virology 1995, 213:439-449.
43. Szilvay A.M., Brokstad K.A., Kopperud R., Haukenes G., Kalland K.H. Nuclear export of the human immunodeficiency virus type 1 nucleocytoplasmic shuttle protein Rev is mediated by its activation domain and is blocked by transdominant negative mutants. J Virol 1995, 69:3315-3323.
44. Tan R., Chen L., Buettner J.A., Hudson D., Frankel A.D. RNA recognition by an isolated alpha helix. Cell 1993, 73:1031-1040.
45. Uchida H., Maeda Y., Mitsuya H. HIV-1 protease does not play a critical role in the early stages of HIV-1 infection. Antiviral Res 1997, 36:107-113.
46. Ueno M., Kodama E.N., Shimura K., Sakurai Y., Kajiwara K., Sakagami S., Oishi S., Fujii N., Matsuoka M. Synonymous mutations in stem-loop III of Rev responsive elements enhance HIV-1 replication impaired by primary mutations for resistance to enfuvirtide. Antiviral Res 2009, 82:67-72.
47. Vodicka M.A., Goh W.C., Wu L.I., Rogel M.E., Bartz S.R., Schweickart V.L., Raport C.J., Emerman M. Indicator cell lines for detection of primary strains of human and simian immunodeficiency viruses. Virology 1997, 233:193-198.
48. Zapp M.L., Hope T.J., Parslow T.G., Green M.R. Oligomerization and RNA binding domains of the type 1 human immunodeficiency virus Rev protein: a dual function for an arginine-rich binding motif. Proc Natl Acad Sci U S A 1991, 88:7734-7738.